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Case report
Acute liver failure in a term neonate after repeated paracetamol 
administration
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ABSTRACT
Objective: Severe hepatotoxicity caused by paracetamol 
is rare in neonates. We report a case of paracetamol-induced 
acute liver failure in a term neonate. 
Case description: A 26-day-old boy was admitted with 
intestinal bleeding, shock signs, slight liver enlargement, 
coagulopathy, metabolic acidosis (pH=7.21; bicarbonate: 
7.1mEq/L), hypoglycemia (18mg/dL), increased serum amino-
transferase activity (AST=4,039IU/L; ALT=1,087IU/L) and 
hyperbilirubinemia (total: 9.57mg/dL; direct: 6.18mg/dL) 
after receiving oral paracetamol (10mg/kg/dose every 4 hours) 
for three consecutive days (total dose around 180mg/kg; 
serum concentration 36–48 hours after the last dose of 77µg/
mL). Apart from supportive measures, the patient was suc-
cessfully treated with intravenous N-acetylcysteine infusion 
during 11 consecutive days, and was discharged on day 34. 
The follow-up revealed full recovery of clinical and of labora-
tory findings of hepatic function. 
Comments: The paracetamol pharmacokinetics and phar-
macodynamics in neonates and infants differ substantially 
from those in older children and adults. Despite the reduced 
rates of metabolism by the P-450 CYP2E1 enzyme system 
and the increased ability to synthesize glutathione — which 
provides greater resistance after overdoses —, it is possible to 
produce hepatotoxic metabolites (N-acetyl-p-benzoquinone) 
that cause hepatocellular damage, if glutathione sources are 
depleted. Paracetamol clearance is reduced and the half-life 
of elimination is prolonged. Therefore, a particular dos-
ing regimen should be followed due to the toxicity risk of 
cumulative doses. This report highlights the risk for severe 
hepatotoxicity in neonates after paracetamol multiple doses 
for more than two to three days.
  
Key-words: acetaminophen; liver failure; infant, newborn; 
N-acetylcysteine.
RESUMO
Objetivo: A hepatoxicidade grave induzida pelo para-
cetamol é muito rara em neonatos. Relata-se o caso de um 
neonato de termo que desenvolveu falência hepática aguda 
após o uso de paracetamol. 
Descrição do caso: Menino, 26 dias, admitido com 
sangramento intestinal, sinais de choque, discreta hepa-
tomegalia, coagulopatia, acidose metabólica (pH=7,21; 
bicarbonato: 7,1mEq/L), hipoglicemia (18mg/dL), au-
mento das aminotransferases séricas (AST=4.039UI/L; 
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ALT=1.087UI/L) e hiperbilirrubinemia (total: 9,57mg/dL; 
direta: 6,18mg/dL), após uso de paracetamol via oral 
(10mg/kg/dose a cada quatro horas) por três dias consecutivos 
(dose total ao redor de 180mg/kg; nível sérico de 36–48 horas 
após a última dose de 77µg/mL). Além das medidas de suporte, 
o paciente foi tratado com N-acetilcisteína (infusão intravenosa 
contínua por 11 dias consecutivos), recebendo alta após 34 dias 
de internação. O seguimento mostrou recuperação clínica e 
dos parâmetros laboratoriais da função hepática. 
Comentários: A farmacocinética e a farmacodinâmica do 
paracetamol em neonatos e lactentes jovens (menores de um 
ano) diferem substancialmente de crianças maiores e adultos. 
Apesar de as taxas de metabolismo do sistema enzimático 
P-450 CYP2E1 estarem diminuídas e a capacidade de gerar 
glutationa, aumentadas — conferindo maior proteção após 
superdosagens —, existe a possibilidade de produção de 
metabólitos hepatotóxicos (N-acetil-p-benzoquinoneimina) 
que determinam lise celular, caso se esgotem as reservas de 
glutationa. A depuração é diminuída e a meia-vida de elimi-
nação é prolongada, recomendando-se posologia distinta pelo 
risco de toxicidade de doses cumulativas. O presente relato 
destaca o risco de hepatotoxicidade grave em neonatos após 
o uso contínuo de paracetamol por mais de dois a três dias.
Palavras-chave: acetaminofen; falência hepática; 
recém-nascido; N-acetilcisteína.
RESUMEN
Objetivo: La hepatotoxicidad grave inducida por el pa-
racetamol es muy rara en neonatos. Se relata el caso de un 
neonato a término que desarrolló falencia hepática aguda 
después del uso de paracetamol. 
Descripción del caso: Niño, 26 días, admitido con sangrado 
intestinal, señales de choque, discreta hepatomegalia, coagulo-
patía, acidosis metabólica (pH=7,21; bicarbonato: 7,1mEq/L), 
hipoglucemia (18mg/dL), aumento de las aminotransferasas 
séricas (AST=4.039UI/L; ALT=1.087UI/L) e hiperbilirrubi-
nemia (total: 9,75mg/dL; directa: 6,18mg/dL), después del uso 
de paracetamol por vía oral (10mg/kg/dosis a cada cuatro horas) 
durante tres días consecutivos (dosis alrededor de 180mg/kg; 
nivel sérico de 36–48 horas después de la última dosis de 
77µg/mL). Además de las medidas de soporte, el paciente fue 
tratado con N-acetilcisteína (infusión intravenosa continua por 
11 días consecutivos), recibiendo alta después de 34 días de 
internación. El seguimiento mostró recuperación clínica y de 
los parámetros laboratoriales de la función hepática.
Comentarios: La farmacocinética y la farmacodinámica 
del paracetamol en neonatos y lactantes jóvenes (menores 
de un año) difieren substancialmente de niños más grandes 
y adultos. A pesar de que las tasas de metabolismo del sis-
tema enzimático P-450 CYP2E1 están reducidas y la capa-
cidad de generar glutatión, aumentada — confiriendo más 
protección después de superdosis —, existe la posibilidad 
de producción de metabólitos hepatotóxicos (N-acetil-p-
benzoquinoneimina) que determinan lisis celular, caso se 
agoten las reservas de glutatión. La depuración es reducida 
y la media vida de la eliminación, alargada, recomendándose 
posología distinta por el riesgo de toxicidad de dosis cumula-
tivas. El presente relato subraya el riesgo de hepatotoxicidad 
grave en neonatos después del uso continuo de paracetamol 
por más de dos a tres días.
Palabras clave: acetaminofeno; falencia hepática; recién 
nacido; N-acetilcisteína.
Introduction
Paracetamol (N-acetyl-p-aminophenol) is a widely used 
analgesic and antipyretic in children; however, toxic expo-
sures are rare in neonates. Toxic exposures may occur via the 
placenta, resulting from intentional ingestion of overdoses 
of paracetamol by mothers in the 24 hours preceding de-
livery(1-3), due to isolated oral(4) or intravenous dosing errors 
(propacetamol, pro-drug of paracetamol, not available in 
Brazil)(5,6), in general, on the order of 10 times the therapeutic 
dose, or due to repeated doses orally(7). 
The severe hepatotoxicity induced by paracetamol, with 
or without acute liver failure, is almost not described in the 
neonatal period. In a review of 97 cases of acute liver failure in 
patients aged <17 years, in two regional reference units of liver 
transplantation in the United Kingdom (1991–2000), there 
were no cases of liver failure by medications in the neonatal 
group (n=17; metabolic diseases – ten cases; infectious diseases – 
seven cases). However, paracetamol was the main product as-
sociated with liver failure (14 out of 19 cases), particularly in the 
age group older than 5 years (n=11), resulting in seven deaths(8). 
Another study analyzed a series of 51 children and adolescents 
who developed hepatotoxicity induced by paracetamol (45 by 
isolated overdose and six by repeated and cumulative doses), all 
with serum levels of aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) >1,000UI/L, and 11 progressed to liver 
failure (encephalopathy and/or coagulopathy). Among these, six 
were submitted to liver transplantation — two survived — and 
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the other five died waiting for transplantation. The youngest 
patient in this series was 10 months old(9). 
In an extensive review conducted by Arana et al, regard-
ing the period from 1978 to 2001, no cases of acetamino-
phen poisoning by direct administration in neonates were 
reported(10). In 2007, Walls et al described the first case of 
liver failure in a term neonate with 4 days of life after the use 
of paracetamol orally for 3 consecutive days (weight 3.1kg; 
26mg/kg/dose every 4 hours on the 1st day; 13mg/kg/dose 
every 4 hours on the 2nd and 3rd days; total cumulative 
dose of approximately 312mg/kg), prescribed as an anal-
gesic postoperatively after a circumcision performed on the 
1st day of life, detecting serum level of acetaminophen of 
109.8µg/mL, 16 hours after the last dose. The patient showed 
complete recovery after continuous intravenous infusion of 
N-acetylcysteine for 36 hours, evolving without sequelae(7). 
The present study described a new case of liver failure in 
term neonate after repeated doses of paracetamol, treated 
successfully with N-acetylcysteine.
Case description
Male patient, 26 days old, weighing 3,125g, son of non-
consanguineous parents, sent by the local emergency unit 
where he remained hospitalized for 24 hours with a history of 
irritability, refusal to eat for 4 days, frequent vomiting for 1 
day, abdominal distension and slight respiratory distress. The 
delivery (iterative cesarean section) was uneventful, and the 
neonate presented birth weight of 3,160g, 48cm, Apgar score 
8 and 10 (1st and 5th minutes), and Capurro score of 39 weeks 
and 3 days. The mother, 38 years old, had 10 previous pregnan-
cies (two cesareans), was confined in a penitentiary since the 5th 
month of pregnancy and had a history of losing custody of nine 
children due to negligence associated with addiction (crack). 
Before admission, the child was exclusively breastfed, on ma-
ternal care in a rooming in prison. The mother reported having 
administered paracetamol orally (10mg/kg/dose every 4 hours 
for 3 consecutive days — total dose of approximately 180mg/kg, 
according to previous prescription to another son), claiming 
that, a week ago the child was weepy and “feverish”. She also 
reported the concomitant use of paracetamol for 5 days for relief 
of toothache (doses and frequency of use were not obtained).
At admission (D1), the child was afebrile with signs of 
shock (heart rate – HR=183bpm, slow capillary refill, weak 
pulse, inaudible blood pressure and mottled skin), jaundice, 
hepatomegaly and massive upper gastrointestinal bleeding. 
The main laboratory findings obtained in the first 24 hours of 
admission included coagulopathy (incoagulable international 
normalized ratio – INR, activated partial thromboplastin 
time – APTT, and thrombin time – TT), metabolic acidosis 
(pH 7,21; bicarbonate 7,1mEq/L; lactate 4,3mmol/L), hypo-
glycemia (18mg/dL), AST – 4,039UI/L, ALT – 1,087UI/L 
and hyperbilirubinemia (total bilirubin – 9.57mg/dL; direct – 
6.18mg/dL). During hospitalization, there was a progressive 
fall in hemoglobin levels: D1 – 10.6g/dL; 3rd day of hospital-
ization (D3) – 8.0g/dL. Serum concentration of paracetamol 
(approximately 36–48 hours after the last dose) was of 77µg/mL 
(therapeutic range of 10–20µg/mL, spectrophotometric 
method). Considering the possibility of consumption by the 
mother and passage through breast milk, a screening of recre-
ational drugs (cocaine, cannabinoids, methamphetamine and 
amphetamine) was performed by an immunochromatographic 
test in the patient’s urine, with negative results. Blood cultures 
collected on admission were also negative.
Supportive measures included: volume replacement, correc-
tion of hypoglycaemia, serial transfusions of fresh frozen plasma, 
dobutamine, mechanical ventilation, empirical antibiotic 
therapy (ampicillin and amikacin in D1-D3, while waiting for 
Table 1 - Main laboratory findings during hospitalization
Day (D) D1 D2 D3 D4 D5 D7 D8 D9 D11 D12 D30
ALT (RV<45UI/L) 1,087 633 339 240 168 107 87 82 79 115 67
AST (RV<60UI/L) 4,039 1,169 319 101 47 34 37 52 94 124 62
Total Bilirubin (RV<1.0mg/dL) 9.6 NR 19.9 26.0 23.3  NR 14.0 11.7 9.4 NR 2.6
Direct Bilirubin (RV<0.3mg/dL) 6.2 NR 18.5 18.4 19.8 NR 8.1 6.6 7.1 4.7 2.1
Paracetamol (TR: 10–20µg/mL) 77 NR NR  NR 11 NR NR NR NR NR NR
INR (RV<1.2) INC 7.9 2.6 2.8 3.3 2.8 NR 1.8 1.4 1.27 1.4
Ammonia (RV=79–150µg/dL)  NR  308 367 410 234 289  NR 241 NR 53 NR
Albumin (RV=2.5–5.5g/dL) NR 2.4 2.0 2.2 2.3 2.2 2.1 2.2 NR NR NR
ALT: alanine aminotransferase; AST: aspartate aminotransferase; RV: reference values; TR: therapeutic range; INR: international normalized ratio; 
NP: examination not performed; INC: incoagulable
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completion of infectious screening), and transfusion of red blood 
cells (D3). After laboratory confirmation of toxic exposure to 
paracetamol, the protocol of continuous intravenous infusion 
of N-acetylcysteine in 21 hours was introduced (150mg/kg in 
60 minutes; 50mg/kg in 4 hours; 100mg/kg in 16 hours)(11), 
maintained at 6.25mg/kg/hour until D11. Given the severity of 
the case and the possibility of progression to liver transplanta-
tion, the patient was transferred to the regional referral unit at 
D3, where he stayed for 19 days. During evolution, there was 
a progressive decrease of aminotransferase concentrations and 
improvement of coagulation; infusion of N-acetylcysteine was 
suspended on D11. The patient developed hospital infection 
by oxacillin-resistant Staphylococcus aureus (D20), treated with 
vancomycin. In Table 1 are summarized the main laboratory 
results achieved during the 34 days of hospitalization. 
In the screening of metabolic diseases that may present 
with liver failure in the neonatal period, the analysis of 
the acylcarnitine profile in D2 showed reduced free serum 
carnitine (5.03mol/L; reference values: 17.8–51.8mol/L), 
with values within the normal range both in the mate-
rial obtained in newborn screening tests and in dosages 
performed after resolution of the clinical condition (D30 
and D180). Research for galactosemia, tyrosinemia, and 
organic acidemia was negative. Prenatal serological testing 
for HIV, toxoplasmosis, syphilis, and hepatitis B and C were 
also negative. The outpatient follow-up undertaken for one 
year showed complete clinical and laboratory recovery and 
adequate neuropsychomotor development.
Discussion
In general, the time of peak absorption following ingestion 
of paracetamol is rapid (30–45 minutes), with analgesic and 
antipyretic action achieved with serum concentrations of 10 
and 4–18μg/mL, respectively, including in children. About 
90% of paracetamol is conjugated in the liver (glucuronida-
tion – 40–67%; sulfation – 20–46%), forming inactive me-
tabolites excreted in the urine. Approximately 5–15% of the 
drug is oxidized in the CYP2E1 and, to a lesser extent in 
the CYP2A6, CYP1A2, and CYP3A4, resulting in the for-
mation of toxic metabolite N-acetyl-p-benzoquinone imine 
(NAPQI), which readily combines with glutathione, turning 
into nontoxic cysteine /mercaptate conjugates eliminated in 
urine. The hepatotoxic action of paracetamol is associated pri-
marily to the activity of the CYP2E1 enzyme system and the 
production of NAPQI(12). In overdoses with clinical repercus-
sion, by isolated overdoses or after supratherapeutic doses, the 
maximum rates of glucuronidation and sulfation are reached 
and the availability of glutathione is insufficient to metabolize 
NAPQI. Then, the free NAPQI binds covalently to hepatic 
proteins of the cysteine group, triggering hepatotoxicity and 
cell death(12,13). Acetaminophen-protein products, such as 
3-(cysteine-S-yl)-paracetamol-adduct are released into the blood 
after hepatocyte lysis. They are measured by high performance 
liquid chromatography with electrochemical detection and may 
be used as specific biomarkers of hepatotoxicity, even several 
days after the exposure(13). A study in adults who developed 
liver failure induced by paracetamol overdoses showed a positive 
correlation between the serum concentration of acetaminophen-
protein adducts and severity of hepatotoxicity, which can be 
detected up to 12 days after ingestion(13). 
In contrast, the pharmacokinetics and pharmacodynamics of 
paracetamol in neonates and young infants (under 1 year) differ 
substantially from older children and adults. The combination 
with glucuronides is immature, while sulfation is well devel-
oped, consisting in the main metabolic pathway(1,2,10,14). The 
clearance of paracetamol in term neonates is decreased and the 
half-life is prolonged compared to that of adults (approximately 
3.5 versus 1.9–2.2 hours), so a distinct dosage is recommended 
(20mg/kg/dose, every 8 hours, no longer than 48 hours of use), 
due to the risk of toxicity of cumulative doses(10,14). In addition, 
the elimination half-life of paracetamol may be extended further 
after multiple doses, in poisoned patients and in those who de-
velop liver failure(2,10,12,14). Although the rates of metabolism of 
CYP2E1 were decreased and the ability to generate glutathione, 
increased, providing greater protection after isolated overdoses, 
neonates may also produce toxic metabolites (NAPQI)(1,10,14), 
triggering up hepatotoxicity and cell lysis if glutathione reserves 
are depleted(10,12,14). It should be noted that paracetamol-protein 
products could also be used as specific biomarkers of hepato-
toxicity in children, especially to assist the diagnosis of acute 
liver failure of unknown etiology(15). 
Even considering the background of the mother, which could 
raise doubts about the actual dose, the continuous use of medica-
tion for 3 days, the possible additional doses transferred through 
breast milk, and the high serum paracetamol levels detected es-
tablished a causal relationship between prolonged use drug and 
liver failure. Reinforcing these findings, Penna and Buchanan 
described in their review the cases of two young infants, 6 
to 7 weeks of life, who also developed severe hepatotoxicity 
after ingesting repeated doses of paracetamol (approximately 
100mg/kg/day/2 days and 60mg/kg/day/6 days, respectively)(16).
N-acetylcysteine  is the antidote of choice in the treatment 
of acetaminophen poisoning, being a precursor of reduced 
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glutathione, which, when given early, can prevent liver dam-
age induced by paracetamol, restoring glutathione levels(11,12,17). 
When the moment of exposure is known, the administration of 
N-acetylcysteine  is formally indicated after ingestion of isolated 
overdoses of paracetamol, when the serum levels, preferably 
obtained between 4 and 8 hours of ingestion are above the 
possible risk line on the Rumack-Matthew nomogram, even 
without clinical or laboratory evidence of liver injury(11,12). When 
the time of exposure is unknown or it is not possible to get the 
serum concentration levels within 8 hours of exposure, but 
the estimated dose is above 200mg/kg in the last 24 hours 
(or ≥10g in adolescents and adults), the use of N-acetylcysteine 
is also indicated, and the decision about the suspension of 
treatment is based on clinical and laboratory progress(11,12,17,18). 
Other more complex situations involve the indication of 
N-acetylcysteine after prolonged or supratherapeutic use 
of paracetamol, when assessing the risk of hepatotoxicity by 
the Rumack-Matthew nomogram is not possible(11,12,17-19). 
In general, it is recommended the use of N-acetylcysteine 
when the serum concentration of paracetamol is above 
10µg/mL or AST>50UI/L(11,12,19). In patients with liver fail-
ure, as described, N-acetylcysteine also  possibly acts as an an-
tioxidant, improving hemodynamics, oxygen consumption, 
and cerebral edema(17). Patients with paracetamol-induced 
liver failure, either by isolated overdoses or by suprathera-
peutic doses, should be given intravenous N-acetylcysteine 
until the encephalopathy resolves itself or until they present 
significant improvements in the results of ALT, INR, and 
creatinine or until liver transplantation(11,17). In the present 
case, continuous intravenous infusion of N-acetylcysteine 
proved to be effective, safe, and without adverse effects, even 
in prolonged use.
Although studies in experimental models suggest that 
carnitine deficiency, as a cause or consequence, may be associ-
ated with hepatotoxicity triggered by acetaminophen(20), it 
would be speculative to infer this association only with the 
data available in the present report (a single measurement 
during the course of liver failure). Clinical studies are needed 
to define and characterize the association more accurately. 
However, it can be inferred that the laboratory screening, the 
evolution, and the outpatient follow-up practically exclude 
the possibility of genetic diseases associated with changes 
in the carnitine transport and the carnitine cycle, which can 
evolve with liver failure(21). 
It is possible to conclude that the continued use of acetamino-
phen can cause severe hepatotoxicity in neonates. The specific 
dosage for term and preterm neonates should be followed, 
avoiding the continuous use for more than 2 to 3 days(10,14). 
